Trial Profile
Phase I Study of the Combination of MLN9708 and Fulvestrant in Patients With Advanced Estrogen Receptor Positive Breast Cancer
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Fulvestrant (Primary) ; Ixazomib (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- Acronyms Millennium
- 01 Jun 2021 Results published in the Oncologist
- 25 Apr 2019 Status changed from recruiting to discontinued.
- 19 Sep 2018 Planned End Date changed from 1 Aug 2019 to 1 Aug 2020.